Eden Research PLC 2023 AR2
The report highlights Eden Research plc's financial and operational performance for the fiscal year 2023, during which total revenue increased by 78% to £3.2m, driven by strong sales of Mevalone and Cedroz. The company successfully launched its first seed treatment, Ecovelex, which received temporary approval in Italy. Additionally, Eden completed a £9.9m fundraise to accelerate product development and expand its market presence. The report also outlines the company's ESG strategy, emphasizing its focus on sustainable biopesticides and plastic-free encapsulation technology to support sustainable agriculture.
Company: Eden Research PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2023
Type: AR2
Pages: 112
Back to company
Eden Research PLC
Annual Report
The report highlights Eden Research plc's financial and operational performance for the fiscal year 2023, during which total revenue increased by 78% to £3.2m, driven by strong sales of Mevalone and Cedroz. The company successfully launched its first seed treatment, Ecovelex, which received temporary approval in Italy. Additionally, Eden completed a £9.9m fundraise to accelerate product development and expand its market presence. The report also outlines the company's ESG strategy, emphasizing its focus on sustainable biopesticides and plastic-free encapsulation technology to support sustainable agriculture.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees